Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1

Conditions

Neoplasm Metastasis 1Mesothelioma 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Ipilimumab 22Fluorouracil 22Azacitidine 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × pevonedistat × Clear all
NCT03319537 2024-05-23

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
9 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma

NCT04800627 2022-12-27

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

M.D. Anderson Cancer Center

Phase 1/2 Terminated
2 enrolled 4 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡